Market revenue in 2023 | USD 4,810.6 million |
Market revenue in 2030 | USD 8,207.2 million |
Growth rate | 7.9% (CAGR from 2023 to 2030) |
Largest segment | Next generation sequencing |
Fastest growing segment | Next Generation Sequencing |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Next Generation Sequencing, QPCR & Multiplexing, LOAC & RT-PCR, Protein Microarrays, DNA Microarrays |
Key market players worldwide | Johnson & Johnson, Illumina Inc, Novartis AG ADR, Roche, Koninklijke Philips NV, Qiagen NV, Agilent Technologies Inc, Abbott Laboratories, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc Common Stock |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to next generation cancer diagnostics market will help companies and investors design strategic landscapes.
Next generation sequencing was the largest segment with a revenue share of 37% in 2023. Horizon Databook has segmented the U.S. next generation cancer diagnostics market based on next generation sequencing, qpcr & multiplexing, loac & rt-pcr, protein microarrays, dna microarrays covering the revenue growth of each sub-segment from 2018 to 2030.
According to the data published by the American Cancer Society, it has been estimated that there were nearly 1,665,540 new cancer cases diagnosed and 585,720 cancer deaths in 2014 in the U.S.
Furthermore, population diagnosed with colorectal cancer was estimated to be 71,830 men and 65,000 women and mortality rate of 26,270 men and 24,040 women was estimated by National Center for Health Statistics.
Additionally, one third of the population (29% of men and 43% of women) were affected, mostly individuals above 80 years and older with substantial variation in tumor location by age.
Horizon Databook provides a detailed overview of country-level data and insights on the U.S. next generation cancer diagnostics market , including forecasts for subscribers. This country databook contains high-level insights into U.S. next generation cancer diagnostics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account